Phase 2 N=29 MEN1611 With Cetuximab in Metastatic Colorectal Cancer (C-PRECISE-01)
Metastatic Colorectal Cancer
Primary: Phase 1b: Recommended Phase 2 Dose (RP2D) of MEN1611 in Combination With Cetuximab — 48 mg
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=14 Preventative Skin Care for Children Undergoing Targeted CNS Tumor Therapy
Pediatric Cancer · CNS Tumor, Childhood · Skin Inflammation
Primary: Rate of Cutaneous Reaction — 7 Participants
Phase 3 N=2,557 A Phase III, Randomized, Study of Aspirin and Esomeprazole Chemoprevention in Barrett's Metaplasia
Esophageal Cancer · Precancerous Condition
Primary: First Event of Death, Oesophageal Adenocarcinoma, High Grade Dysplasia — 127; 154; 174; 139 Participants — p=0.068
Phase 3 N=340 Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery
Cervical Adenocarcinoma · Cervical Adenosquamous Carcinoma · Cervical Squamous Cell Carcinoma, Not Otherwise Specified
Primary: Recurrence-free Survival (RFS) Rate at 3-years — 85.4; 88.5 percentage of participants — p=0.0927
Phase 2 N=9 Evaluation of [18F]Fluoroethyl Triazole Labelled [Tyr3]-Octreotate Analogues for the Imaging of Neuroendocrine Tumours.
Neuroendocrine Tumors
Primary: To Determine the Biodistribution of [18F] Following Single I.V Administration of [18F]-FET-βAG-TOCA Injection in Patients With a Histological Diagnosis of NET. — 0.002…
N/A N=269 The PATH Home Trial: A Comparative Effectiveness Study of Peripartum Opioid Use Disorder in Rural Kentucky
Neonatal Abstinence Syndrome
Primary: Percent of Infants Diagnosed With Neonatal Abstinence Syndrome (NAS) Requiring Medication Treatment — 24.1; 33.3 % infants requiring medication for NAS
N/A N=82 Postoperative Hip Bracing After Hip Arthroscopy
Femoroacetabular Impingement Syndrome · Acetabular Labral Tear
Primary: Patient Numerical Pain Ranking Scale (NPRS) — 1.8; 2.3 score on a scale
Phase 2 N=62 Melphalan Hydrochloride in Treating Participants With Newly-Diagnosed Multiple Myeloma Undergoing Donor Stem Cell Transplantation
Plasma Cell Myeloma
Primary: Optimal Dose and Schedule of Evomela Prior to Autologous Transplant. — 0; 0; 0; 0 Participants
Phase 3 N=552 A Non-inferiority, Comparative Study Between Foraseq®, Eurofarma´s Formoterol/Budesonide and Alenia® in Asthma
Asthma
Primary: Forced Expiratory Volume in 1 Second (FEV1) at the Final Visit (FV) — 2.53; 2.51 Liter
Phase 2 N=11 TJ-68 Clinical Trial in Patients With Amyotrophic Lateral Sclerosis (ALS) and Muscle Cramps
Amyotrophic Lateral Sclerosis · Muscle Cramp
Primary: Visual Analog Scale (MCS-VAS) Score — 2.07; 1.7 score on a scale
N/A N=102 Reliability and Validity of Inline Dynamometry Study for Measuring Knee Extensor Torque
Anterior Cruciate Ligament Injuries · Anterior Cruciate Ligament Rupture · Anterior Cruciate Ligament Tear
Primary: Peak Knee Extensor Torque Measured in Newton Metres Per kg (Nm/kg) — 3.12; 2.66 Newton metres per kg
Phase 3 N=37 A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Severe Hemophilia A
Hemophilia A
Primary: Total Annualized Bleeding Rates (ABR) — 4.1 bleeds per year
N/A N=39 Effect of Cocoa Supplementation Peripheral and Autonomic Diabetic Neuropathy
Diabetic Neuropathies
Primary: Toronto Clinical Scoring System (TCSS) — -2.63; -1.84; 9.31; 6.89 Score on a scale — p=>0.05
N/A N=68,563 Patients With Geographic Atrophy and Their Patient Journey in the United States (US)
Geographic Atrophy
Primary: Change in Visual Acuity (VA) in Participant's Study Eye — -2.8; -5.9; -8.6; -10.3 Letters read
Phase 2 N=20 An Inflammatory Challenge Using Endotoxin
Alcohol Use Disorder · Inflammatory Response · Craving
Primary: Cue-induced Craving — 4.5004; 7.9081; 4.5004; 5.6178 score on a scale — p=0.036